CA2907178A1 - Ido inhibitors - Google Patents

Ido inhibitors

Info

Publication number
CA2907178A1
CA2907178A1 CA2907178A CA2907178A CA2907178A1 CA 2907178 A1 CA2907178 A1 CA 2907178A1 CA 2907178 A CA2907178 A CA 2907178A CA 2907178 A CA2907178 A CA 2907178A CA 2907178 A1 CA2907178 A1 CA 2907178A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
mmol
compounds
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2907178A
Other languages
English (en)
French (fr)
Inventor
James Aaron Baldog
Audris Huang
Bin Chen
Libing Chen
Weifang Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2907178A1 publication Critical patent/CA2907178A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CA2907178A 2013-03-15 2014-03-12 Ido inhibitors Abandoned CA2907178A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361787939P 2013-03-15 2013-03-15
US61/787,939 2013-03-15
PCT/US2014/023877 WO2014150646A1 (en) 2013-03-15 2014-03-12 Ido inhibitors

Publications (1)

Publication Number Publication Date
CA2907178A1 true CA2907178A1 (en) 2014-09-25

Family

ID=50391513

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2907178A Abandoned CA2907178A1 (en) 2013-03-15 2014-03-12 Ido inhibitors

Country Status (19)

Country Link
US (1) US9624188B2 (OSRAM)
EP (1) EP2970114B1 (OSRAM)
JP (1) JP6313415B2 (OSRAM)
KR (1) KR20150129010A (OSRAM)
CN (1) CN105324362B (OSRAM)
AU (1) AU2014235816B2 (OSRAM)
BR (1) BR112015022462A8 (OSRAM)
CA (1) CA2907178A1 (OSRAM)
EA (1) EA028424B1 (OSRAM)
ES (1) ES2733546T3 (OSRAM)
HK (1) HK1220442A1 (OSRAM)
IL (1) IL241321A0 (OSRAM)
MA (1) MA38483A1 (OSRAM)
MX (1) MX2015012056A (OSRAM)
PE (1) PE20151594A1 (OSRAM)
PH (1) PH12015502028A1 (OSRAM)
SG (1) SG11201506920QA (OSRAM)
WO (1) WO2014150646A1 (OSRAM)
ZA (1) ZA201506796B (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (OSRAM) 2011-04-15 2018-03-17
EP2970155B1 (en) 2013-03-15 2018-04-25 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (ido)
CN105473550B (zh) 2013-07-01 2019-02-15 百时美施贵宝公司 Ido抑制剂
ES2707961T3 (es) * 2013-07-11 2019-04-08 Bristol Myers Squibb Co Inhibidores de IDO
ES2811345T3 (es) 2015-03-23 2021-03-11 Jounce Therapeutics Inc Anticuerpos contra ICOS
JP2018519245A (ja) * 2015-04-03 2018-07-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法
US10689331B2 (en) 2015-06-26 2020-06-23 Bristol-Myers Squibb Company IDO inhibitors
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
CR20180023A (es) 2015-07-24 2018-03-20 Newlink Genetics Corp Sales y profármacos de 1-metil-d-triptofano
CN108368049A (zh) * 2015-09-24 2018-08-03 葛兰素史克知识产权开发有限公司 吲哚胺2,3-双加氧酶的调节剂
CN108601767A (zh) * 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
TW201723190A (zh) 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
AU2017217536A1 (en) * 2016-02-09 2018-08-09 Inventisbio Inc. Inhibitor of indoleamine-2,3-dioxygenase (IDO)
US11752131B2 (en) 2016-02-19 2023-09-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of obesity
BR112018071602B1 (pt) * 2016-04-29 2024-02-27 Iomet Pharma Ltd. Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase
CA3023034A1 (en) * 2016-05-12 2017-11-16 Glaxosmithkline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
JOP20170131B1 (ar) * 2016-06-10 2021-08-17 Lilly Co Eli مركبات 1-تيترا هيدروبيرانييل كاربونيل -2،3-ديهيدرو -1 h- اندول لعلاج السرطان
WO2018036414A1 (zh) * 2016-08-23 2018-03-01 北京诺诚健华医药科技有限公司 稠杂环类衍生物、其制备方法及其在医学上的应用
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
CN110381963A (zh) 2016-10-13 2019-10-25 朱诺治疗学股份有限公司 涉及色氨酸代谢途径调节剂的免疫治疗方法和组合物
MD3535298T2 (ro) 2016-11-02 2022-01-31 Jounce Therapeutics Inc Anticorpi ai PD-1 și utilizări ale acestora
EP3534933B1 (en) 2016-11-04 2025-01-01 Aximmune, Inc. Beta-alethine in combination with immune modulators and uses thereof
US10899754B2 (en) 2016-12-20 2021-01-26 Glaxosmithkline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
MX378460B (es) 2016-12-22 2025-03-10 Calithera Biosciences Inc Composiciones y métodos para inhibir la actividad de la arginasa.
US11173145B2 (en) 2017-01-17 2021-11-16 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
EP3694506B1 (en) 2017-10-09 2023-08-02 Merck Sharp & Dohme LLC Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN109836356B (zh) * 2017-11-24 2022-03-08 沈阳化工研究院有限公司 一种芳甲醚衍生物及其应用
CN111699196A (zh) 2017-12-22 2020-09-22 震动疗法公司 针对lilrb2的抗体
US11447449B2 (en) * 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11813280B2 (en) 2018-01-05 2023-11-14 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
JP2021523213A (ja) 2018-05-14 2021-09-02 ジャウンス セラピューティックス， インク．Ｊｏｕｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 癌を治療する方法
WO2020018670A1 (en) 2018-07-17 2020-01-23 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020081905A1 (en) 2018-10-18 2020-04-23 Jounce Therapeutics, Inc Methods for treating cancer
EP3870610A1 (en) 2018-10-24 2021-09-01 Jounce Therapeutics, Inc. Methods and compositions for the treatment of cancer and infectious diseases
US20210355222A1 (en) 2018-10-26 2021-11-18 Jounce Therapeutics, Inc. Methods of Treating Cancer
WO2020185739A1 (en) 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
EP4055052A1 (en) 2019-11-05 2022-09-14 Jounce Therapeutics, Inc. Methods of treating cancer with anti-pd-1 antibodies
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
WO2021102618A1 (en) * 2019-11-25 2021-06-03 InventisBio Co., Ltd. Novel salts of indoleamine 2,3-dioxygenase inhibitors
EP4090771A1 (en) 2020-01-13 2022-11-23 Jounce Therapeutics, Inc. Methods for the treatment of cancer
CN111153846B (zh) * 2020-01-17 2021-08-31 中国药科大学 吡咯类化合物、其制备方法和药物组合物与用途
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
WO2023235699A1 (en) 2022-05-31 2023-12-07 Jounce Therapeutics, Inc. Antibodies to lilrb4 and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447957A (en) * 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体（ＰＰＡＲ）αアゴニストとしての置換フェニルプロピオン酸誘導体
WO2002046146A1 (fr) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
US7056925B2 (en) * 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
ES2340179T3 (es) * 2004-05-12 2010-05-31 Bristol-Myers Squibb Company Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas.
EP1804785A2 (en) * 2004-10-27 2007-07-11 Neurogen Corporation Diaryl ureas as cb1 antagonists
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2009132238A2 (en) * 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
EP2970155B1 (en) 2013-03-15 2018-04-25 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (ido)

Also Published As

Publication number Publication date
PH12015502028A1 (en) 2016-01-18
WO2014150646A1 (en) 2014-09-25
EA028424B1 (ru) 2017-11-30
BR112015022462A8 (pt) 2019-11-26
AU2014235816A1 (en) 2015-11-05
AU2014235816B2 (en) 2018-05-17
EP2970114A1 (en) 2016-01-20
BR112015022462A2 (pt) 2017-07-18
JP6313415B2 (ja) 2018-04-18
MX2015012056A (es) 2015-12-16
JP2016518324A (ja) 2016-06-23
HK1220442A1 (zh) 2017-05-05
CN105324362A (zh) 2016-02-10
IL241321A0 (en) 2015-11-30
MA38483A1 (fr) 2018-02-28
PE20151594A1 (es) 2015-11-19
SG11201506920QA (en) 2015-09-29
US20160060237A1 (en) 2016-03-03
CN105324362B (zh) 2017-05-24
ES2733546T3 (es) 2019-11-29
US9624188B2 (en) 2017-04-18
EA201591823A1 (ru) 2016-01-29
EP2970114B1 (en) 2019-05-15
KR20150129010A (ko) 2015-11-18
ZA201506796B (en) 2017-08-30

Similar Documents

Publication Publication Date Title
AU2014235816B2 (en) IDO inhibitors
DK2970155T3 (en) INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
EP3019488B1 (en) Ido inhibitors
EP3016932A1 (en) Ido inhibitors
CA2981584A1 (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
US10689331B2 (en) IDO inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190312

FZDE Discontinued

Effective date: 20210913

FZDE Discontinued

Effective date: 20210913